MedTrace Logo

Orientation in AD Patients: PET-MR Study

NCT03030365 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 30

Last updated 2017-01-25

No results posted yet for this study

Summary

Despite the high prevalence of Alzheimer's disease (AD), its underlying mechanisms remain poorly understood. An emerging body of evidence supports disorientation as an early marker for AD-related neurodegeneration. In this study we intend to collect, coregister and analyze Positron Emission Tomography (PET) and , functional and structural magnetic resonance imaging (MRI, fMRI) data from AD-spectrum patients to establish orientation as core disturbance in AD.

Conditions

Interventions

DEVICE

Siemens "Biograph mMR" PET-MR (3T)

Standardly used Magnetic resonance imaging (MRI) protocols, including resting state fMRI, task fMRI, T1 weighted imaging. In addition Patients will receive an intravenous injection of 2-5mCi of 18F-FDG prior to PET MRI.

Sponsors & Collaborators

  • Hadassah Medical Organization

    collaborator OTHER

  • Assuta Medical Center

    lead OTHER

Principal Investigators

  • David Groshar, MD · Head of nuclear medicine unit in Assuta Medical Centers

Eligibility

Min Age
50 Years
Max Age
79 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-02-15
Primary Completion
2019-02-15
Completion
2020-02-15

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03030365 on ClinicalTrials.gov